Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10352 in advanced breast cancer
NCT04631835Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2020
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS-10352 in Hormone-Receptor-Positive Breast Cancer, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose Limiting Toxicity at 35 days and Maximum Tolerated Dose at 35 days. Status: unknown.
02
Drugs
HS-10352
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT04631835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04631835.